Abstract 46P
Background
ABCB1 gene reported to affect chemo-induced toxicity through drug disposition and efflux mechanisms. This study aims to evaluate the influence of ABCB1 (C1236T, G2677T/A, C3435T) polymorphisms on, chemotoxicity, and survival outcomes in BC patients treated with anthracycline and taxane either sequentially or concomitantly.
Methods
100 patients were included who received sequential or concomitant anthracycline and taxane as per clinician discretion and underwent modified radical mastectomy. Chemotoxicity grade was analyzed by CTCAE v.4. All patients received standard premedication with 5HT3, NK1 receptor antagonist, dexamethasone, H2 blocker/ PPI. SNP of ABCB1 (C1236T, G2677T/A, C3435T) gene was detected by PCR-RFLP and sequencing.
Results
Patients mostly reported at Stage III (52.89%) with infiltrating ductal carcinoma subtype (90.9%) who received sequential (50%) & concomitant (50%) chemotherapy. Grade ≥2 chemo toxicity like neutropenic fever, significantly associated with C1236T SNP with odd ratio (OR) for TT genotypes was 2.00 (95% CI: 0.125-31.975, p=0.000), while in CT genotypes, it stood at 1.100 (95% CI: 0.063-15.988; p = 0.035). Meanwhile, vomiting was significantly associated with C3435T for TT genotypes, with an OR of 3.031 (95% CI: 0.031-7.994, p=0.05). TT genotypes (C1236T) were significantly associated with nausea (OR: 2.667; 95% CI: 1.043-6.815; p = 0.04). Alopecia was observed 88% patients. However, ABCB1 showed no significant (p = 0.416, Log-rank) correlation for overall survival. Although, no significant associations were found for G2677T/A in terms of toxicity and survival.
Conclusions
The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. D. Nasare.
Funding
This work is funded by Council of Scientific and Industrial Research, Government of India, File No. 09/030(0085)/2019-EMR-I awarded to Tanuma Mistry.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
561P - Mechanisms of osimertinib resistance using circulating tumor DNA analyses for EGFR-mutated non-small cell lung cancer, results from ELUCIDATOR: A prospective observational multicenter study
Presenter: Daijiro Harada
Session: Poster Display
Resources:
Abstract
562P - First-line (1L) osimertinib (osi) ± platinum-pemetrexed in patients (pts) with EGFRm advanced NSCLC: FLAURA2 China cohort
Presenter: Yan Yu
Session: Poster Display
Resources:
Abstract
563P - Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
Presenter: Jianya Zhou
Session: Poster Display
Resources:
Abstract
564P - Co-occurring EGFR p.E709X mutation affects the treatment response to the third-generation EGFR-TKIs in EGFR p.G719X-mutant patients with advanced NSCLC
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
565P - Genome-guided targeted therapy combination improves survival in patients with advanced EGFR mutation positive NSCLC failing osimertinib
Presenter: Molly Li
Session: Poster Display
Resources:
Abstract
566P - Safety of tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification after first-line osimertinib
Presenter: Chong Kin Liam
Session: Poster Display
Resources:
Abstract
567P - Furmonertinib in combination with bevacizumab and intrathecal chemotherapy as later-line re-challenge treatment in EGFR –mutated NSCLC patients with leptomeningeal metastasis after third-generation EGFR-TKIs treatment failure
Presenter: Fang Cun
Session: Poster Display
Resources:
Abstract
568P - First-line (1L) osimertinib + platinum-pemetrexed in EGFR-mutated (EGFRm) advanced NSCLC: Updated FLAURA2 safety run-in (SRI) results
Presenter: David Planchard
Session: Poster Display
Resources:
Abstract
569P - Whole-transcriptome sequencing of transformed small-cell lung cancer from EGFR-mutated lung adenocarcinoma reveals LUAD–like and SCLC–like subsets
Presenter: Chan-Yuan Zhang
Session: Poster Display
Resources:
Abstract
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract